Toujeo (previously Optisulin)

RSS

insulin glargine

Authorised
This medicine is authorised for use in the European Union.

Overview

Toujeo is a medicine used to control blood glucose (sugar) levels in adults and children from 6 years of age who have diabetes and need insulin.

It contains the active substance insulin glargine.

This EPAR was last updated on 04/09/2020

Authorisation details

Product details
Name
Toujeo (previously Optisulin)
Agency product number
EMEA/H/C/000309
Active substance
insulin glargine
International non-proprietary name (INN) or common name
insulin glargine
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AE04
Publication details
Marketing-authorisation holder
Sanofi-aventis Deutschland GmbH
Revision
30
Date of issue of marketing authorisation valid throughout the European Union
26/06/2000
Contact address
D-65926 Frankfurt am Main
Germany

Product information

10/08/2020 Toujeo (previously Optisulin) - EMEA/H/C/000309 - IAIN/0114

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
2 ratings